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target for the surveillance of plasmodial
atovaquone/proguanil resistance has to be
questioned.
Ole Wichmann and Tomas Jelinek
Berlin Institute of Tropical Medicine,
Berlin, Germany
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Drug Resistance and Fitness
in Mycobacterium
tuberculosis Infection
To the Editor—In a recent article, Burgos
et al. [1] investigated the effect of drug
resistance on the generation of secondary
cases of tuberculosis, because previous
studies have yielded contradictory data
on the pathogenicity and transmission of
drug-resistant strains of Mycobacterium
tuberculosis [2]. On the basis of epide-
miological data, those authors quantified
the number of secondary cases generated
by drug-resistant versus drug-susceptible
strains, to calculate the relative secondary
case-rate ratio (SR). They concluded that,
in the context of an effective tuberculosis
control program, strains that were resis-
tant to isoniazid either alone or in com-
bination with other drugs were less likely
to result in secondary cases than were
drug-susceptible strains. However, there
were large differences in SRs for resistance
to different drugs, such as a decrease in
SR for isoniazid resistance (SR, 0.29), no
effect on SR for streptomycin resistance
(SR, 0.88), and an increase in SR for ri-
fampicin resistance (SR, 2.33). Unless
there are convincing reasons provided to
explain these differences, these findings
might indicate that the parameters of the
study and the methods of analyses were
not very robust. It is particularly diffi-
cult to explain why rifampicin resistance
should increase the number of secondary
cases. A priori, there is no reason why
drug resistance should increase the SR,
unless one assumes general factors, such
as prolonged transmission due to inef-
fective drug treatment. This should, how-
ever, affect the drugs equally, if standard
treatment procedures are used.
Experimental data and mathematical
models have suggested that the reduction
of bacterial fitness (i.e., reduced transmis-
sion between hosts and reduced persis-
tence and growth within hosts) imposed
by antimicrobial resistance could influ-
ence the frequency of drug-resistant mi-
croorganisms in a population [3, 4]. In
this respect, we refer to a very eloquent
article by G. Canetti [5]. Canetti addressed
the question of resistance-related fitness
costs by studying, at a phenotypic level,
the resistance observed in primary drug-
resistant strains versus those with acquired
drug resistance (primary resistance is de-
fined as infection with a resistant strain;
acquired resistance is defined as drug re-
sistance that emerges during chemother-
apy). In contrast to acquired resistance,
primary resistance reflects additional pa-
rameters, such as fitness and transmission.
Canetti found that, for isoniazid but not
for streptomycin, the proportion of high-
level drug resistance was considerably
lower for strains with primary resistance
than for strains with acquired resistance.
This seemed to indicate that, in contrast
to streptomycin, high-level isoniazid re-
sistance is associated with a defined fit-
ness cost.
The results of epidemiological investi-
gations are complemented by studies that
have examined the mechanisms of drug
resistance at a molecular level, particularly
those that have addressed the question of
fitness cost related to the acquisition of a
resistance determinant. Although corre-
sponding studies in mycobacteria have
been scarce [6–10], some of them have
provided interesting insights, such as those
that relate to resistance to streptomycin
and to isoniazid.
The fitness cost of various chromo-
somal mutations was experimentally de-
termined and was found to be depen-
dent on the chromosomal alteration that
mediates resistance to streptomycin [9].
Drug-resistant mutants obtained by in vi-
tro selection in the laboratory are char-
acterized by a variety of different possible
resistance mutations. In contrast, strepto-
mycin resistance in clinical M. tuberculosis
isolates nearly invariably is associated with
the lysinerarginine alteration at amino
acid 42 of rpsL [7]. Interestingly, the ly-
sinerarginine alteration at amino acid 42
of rpsL is the only streptomycin resistance
determinant among the mutational alter-
ations studied that was found to not carry
a fitness cost, as determined experimentally
in vitro [9]. These basic molecular studies
provide a mechanistic explanation for the
pioneering epidemiological observations by
Canetti.
Most of the many chromosomal alter-
ations that result in resistance to isoniazid
are associated with a significant fitness cost
[6, 8], although the seriner threonine re-
sistance mutation at amino acid 315 of
KatG was found to not affect in vivo
growth in an experimental animal model
[8]. In accordance with the early find-
ings of Canetti [5] and the results reported
by Burgos et al. [1], it was found that
isoniazid-resistant strains in general were
significantly less clustered than were iso-
niazid-susceptible strains [11]. However,
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more-refined analysis of the epidemiolog-
ical data revealed that aa-315 isoniazid-
resistant mutants led to secondary cases
of tuberculosis as often as drug-susceptible
strains [12].
A picture emerges in which, among
various resistance mutations that appear
with similar rates, those associated with
the least fitness cost are most likely to
become selected in the population. To al-
low the implementation of rational strat-
egies to combat the problem of drug-re-
sistant tuberculosis, we need an integrated
view that combines epidemiology, molec-
ular mechanisms of resistance, and a rel-
evant experimental determination of how
drug resistance affects the entire life cy-
cle of M. tuberculosis (the establishment
of infection, progression to disease, and
transmission).
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Reply to Bo¨ttger et al.
To the Editor—We appreciate the com-
ments of Bo¨ttger et al. [1] concerning our
recently published article [2]. In our analy-
sis, we estimated the number of secondary
cases that arose from all drug-suscepti-
ble and drug-resistant cases by assuming
that strains were transmitted to other pa-
tients if the drug-susceptibility test results
and genotype patterns were identical. We
calculated the number of secondary cases
for each drug-resistance pattern and de-
termined the secondary-case rate ratio
(SR). Bo¨ttger et al. questioned the large
differences in SRs, especially the increased
SR for rifampin-resistant cases. The most
likely explanation for the high SR observed
among rifampin-resistant cases was the in-
creased incidence of HIV infection among
patients with this resistance pattern. We
found that the secondary cases caused by
rifampin-resistant strains occurred mainly
among patients with HIV infection; 77.8%
(7/9) of the secondary cases with rifampin
resistance occurred in HIV-positive indi-
viduals [1]. In addition, almost every case
of rifampin-resistant tuberculosis in San
Francisco was in an HIV-infected individ-
ual. Therefore, it is difficult to draw con-
clusions about the effect of rifampin re-
sistance on bacterial fitness. The heteroge-
neity of SR values found among persons
with infections resistant to isoniazid and to
streptomycin in our study are in agreement
with the literature cited by Bo¨ttger et al., so
it is not clear why the authors are puzzled
by these findings. We concur with Bo¨ttger
et al. that the application of epidemiological
methodologies, in conjunction with mo-
lecular and genomic tools, is needed to
achieve a more refined understanding of
the biology of drug-resistant tuberculosis in
its natural population.
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